Suppr超能文献

经口崩解薄膜和经口崩解片传递米氮平微粉化制剂。

Micronized Zaleplon Delivery via Orodispersible Film and Orodispersible Tablets.

机构信息

Department of Pharmaceutics and Drug Delivery, The University of Mississippi, University, Oxford, MS, 38677, USA.

Roquette America Inc., Geneva, IL, 60134, USA.

出版信息

AAPS PharmSciTech. 2018 Apr;19(3):1358-1366. doi: 10.1208/s12249-017-0924-9. Epub 2018 Jan 19.

Abstract

The following research study focuses on improving the solubility of zaleplon (BCS class II drug) via micronization technique in order to enhance its oral delivery in orodispersible formulations. Zaleplon along with a surfactant solution was micronized by ultrasonication. The micronization process reduced the particle size of the crystalline drug about six-fold from its original size of 155.5 μm. The micronized zalepon dispersion was lyophilized to allow for a change in the state of matter (to a powder). The superior dissolution parameters (Q, Q, IDR, MDR, MDT, DE, and RDR) of zaleplon in microcrystalline form over the original crystalline form in in vitro dissolution studies had unraveled that micronization technique is an efficient tool in enhancing drug solubility. The micronized zaleplon solid dispersion (after lyophilization) was loaded into orodispersible tablet (ODT) and orodispersible film (ODF) formulations. The positive quality of ODT with adequate hardness and smooth texture was attributing to the presence of Pearlitol Flash® as a ready to use ODT platform. On the other hand, the ODF loaded with micronized zaleplon and prepared with Lycoat® RS 720 (as a film former) ensured adequate tensile strength. The disintegration time of ODT and ODF was 30 ± 5 and 35 ± 5 s, respectively. Thus, the orodispersible formulations containing micronized zaleplon have a strong potential for rapid disintegration following superior absorption in solution state through oral cavity into the blood stream, envisaging better oral delivery.

摘要

本研究旨在通过微粉化技术提高扎来普隆(BCS 类 II 药物)的溶解度,以增强其在口腔速溶制剂中的口服递送。将扎来普隆与表面活性剂溶液通过超声微粉化。微粉化过程将结晶药物的粒径从原始的 155.5 μm 缩小约六倍。将微粉化的扎来普隆分散体冷冻干燥,使物质状态发生变化(变为粉末)。在体外溶解研究中,微结晶形式的扎来普隆的优越溶解参数(Q、Q、IDR、MDR、MDT、DE 和 RDR)超过原始结晶形式,表明微粉化技术是提高药物溶解度的有效工具。冷冻干燥后的微粉化扎来普隆固体分散体(SD)被载入口腔速溶片(ODT)和口腔速溶膜(ODF)制剂中。ODT 具有足够的硬度和平滑的质地,这是由于存在可直接使用的 ODT 平台——山梨醇闪蒸颗粒(Pearlitol Flash®)。另一方面,载入微粉化扎来普隆并使用 Lycoat® RS 720(成膜剂)制备的 ODF 确保了足够的拉伸强度。ODT 和 ODF 的崩解时间分别为 30±5 和 35±5 s。因此,含有微粉化扎来普隆的口腔速溶制剂具有快速崩解的潜力,在口腔中迅速溶解并吸收进入血液,有望实现更好的口服递送。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验